A Tefferi

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
  2. ncbi request reprint Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1724-5. 2006
  3. doi request reprint Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 36:1481-9. 2012
  4. pmc WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
    M M Patnaik
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1283-9. 2010
  5. pmc Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1322-7. 2013
  6. pmc Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
    D Caramazza
    Cattedra ed UO di Ematologia, Policlinico Universitario di Palermo, Palermo, Italy
    Leukemia 25:82-8. 2011
  7. pmc Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
    A Tefferi
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Blood Cancer J 1:e7. 2011
  8. pmc Personalized management of essential thrombocythemia-application of recent evidence to clinical practice
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 27:1617-20. 2013
  9. pmc Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
    A Tefferi
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1874-81. 2013
  10. doi request reprint JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:2721-30. 2012

Collaborators

Detail Information

Publications190 found, 100 shown here

  1. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
    ..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
  2. ncbi request reprint Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1724-5. 2006
  3. doi request reprint Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 36:1481-9. 2012
    ....
  4. pmc WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
    M M Patnaik
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1283-9. 2010
    ....
  5. pmc Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1322-7. 2013
    ..CYT387 is well tolerated and produces significant anemia, spleen and symptom responses in MF patients. Plasma cytokine and gene expression studies suggested a broad anticytokine drug effect...
  6. pmc Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
    D Caramazza
    Cattedra ed UO di Ematologia, Policlinico Universitario di Palermo, Palermo, Italy
    Leukemia 25:82-8. 2011
    ..5, 95% CI: 2.5-12.0; P<0.0001). This study provides the rationale and necessary details for incorporating cytogenetic findings and platelet count in future prognostic models for PMF...
  7. pmc Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
    A Tefferi
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Blood Cancer J 1:e7. 2011
    ....
  8. pmc Personalized management of essential thrombocythemia-application of recent evidence to clinical practice
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 27:1617-20. 2013
    ..In so doing, we are fully cognizant and sympathetic of the fact that some of our recommendations need to be tested in prospective controlled studies. ..
  9. pmc Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
    A Tefferi
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1874-81. 2013
    ..Leukemic transformation was associated with treatment exposure to pipobroman or P32/chlorambucil. We found no association between leukemic transformation and hydroxyurea or busulfan use...
  10. doi request reprint JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:2721-30. 2012
    ....
  11. pmc IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:475-80. 2012
    ..Our observations suggest that IDH mutations in PMF are independent predictors of leukemic transformation and raise the possibility of leukemogenic collaboration with JAK2V617F...
  12. doi request reprint Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms
    Animesh Pardanani
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1087-94. 2012
    ..Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest...
  13. doi request reprint Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 87:285-93. 2012
    ..Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus, and a small risk of disease progression into acute myeloid leukemia or myelofibrosis...
  14. pmc If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center
    Colin M Segovis
    Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    BMC Med Educ 7:22. 2007
    ..The present study examined whether attendance at medical grand rounds increased after providing complimentary food to attendees and also assessed attendee attitudes about complimentary food...
  15. ncbi request reprint The diagnosis of polycythemia vera: new tests and old dictums
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:455-69. 2006
    ..Recent discoveries of myeloproliferative-disease-specific molecular markers, including the JAK2 V617F tyrosine kinase mutation that is found in the majority of patients with PV, provide further support for such a measure...
  16. ncbi request reprint Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:75-83. 2005
    ....
  17. ncbi request reprint Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester 55905, USA
    Best Pract Res Clin Haematol 19:365-85. 2006
    ..Such progress is paving the way for a transition from a histologic to a semi-molecular classification system that preserves conventional terminology, while incorporating new information on molecular pathogenesis...
  18. doi request reprint Pomalidomide is active in the treatment of anemia associated with myelofibrosis
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester MN 55905, USA
    J Clin Oncol 27:4563-9. 2009
    ..However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...
  19. doi request reprint Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN, USA
    Leuk Res 33:662-4. 2009
    ..This preliminary report suggests a potential value for array CGH in terms of both clinical diagnostics and genomic research in MPNs...
  20. doi request reprint Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 51:576-82. 2010
    ..Current information on mutational status and response to JAK2 inhibitor drug therapy is too preliminary to draw any conclusions...
  21. ncbi request reprint Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera
    Michelle A Elliott
    Mayo Clinic, 200 First Street SW, West 10 A, Division of Hematology, Rochester, MN 55905, USA E mail
    Curr Hematol Rep 3:344-51. 2004
    ..Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV...
  22. ncbi request reprint Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Hematol 79:441-7. 2004
    ..The bone marrow histologic phenotype of these imatinib-sensitive eosinophilic disorders includes systemic mastocytosis, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, and atypical chronic myeloproliferative disorder...
  23. ncbi request reprint Systemic mastocytosis: current concepts and treatment advances
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Curr Hematol Rep 3:197-202. 2004
    ..Cladribine has been shown to be effective in patients who develop resistance to interferon treatment...
  24. ncbi request reprint The indolent natural history of essential thrombocythemia: a challenge to new drug development
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:97-8. 2005
  25. pmc Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1128-38. 2010
    ..However, it is not clear as to whether and how these abnormalities contribute to disease initiation, clonal evolution or blastic transformation...
  26. pmc IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1302-9. 2010
    ..The current study clarifies disease- and stage-specific IDH mutation incidence and prognostic relevance in MPN and provides additional evidence for the biological effect of distinct JAK2 haplotypes...
  27. ncbi request reprint The diagnostic interface between histology and molecular tests in myeloproliferative disorders
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Hematol 14:115-22. 2007
    ..This review discusses how this process is unfolding in myeloproliferative disorders...
  28. doi request reprint Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:573-82. 2011
    ..The unmet need for treatment in PMF dictates a different approach for assessing the therapeutic value of new drugs (eg, JAK inhibitors, pomalidomide) or allogeneic stem-cell transplantation...
  29. ncbi request reprint Eosinophilia: secondary, clonal and idiopathic
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:468-92. 2006
    ..The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment...
  30. ncbi request reprint Mutation screening for JAK2V617F: when to order the test and how to interpret the results
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:739-44. 2006
    ..Therefore, mutation screening for JAK2V617F can be considered as a myeloid-specific clonality assay and it is diagnostically most useful in the evaluation of "polycythemia"...
  31. ncbi request reprint Essential thrombocythemia: scientific advances and current practice
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Hematol 13:93-8. 2006
    ....
  32. ncbi request reprint New insights into the pathogenesis and drug treatment of myelofibrosis
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Hematol 13:87-92. 2006
    ..Advances have also been meager in terms of treatment for disease complications, including anemia, splenomegaly, and leukemic transformation...
  33. doi request reprint JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 24:105-9. 2010
    ..Allelic distortion from acquired uniparental disomy contributes to the appearance of a more pronounced effect on disease susceptibility in VF-positive patients, when studying clonally affected tissue...
  34. ncbi request reprint The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
    Ayalew Tefferi
    Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer 106:631-5. 2006
    ..Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study...
  35. ncbi request reprint Pathogenesis of myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 23:8520-30. 2005
    ..This latter phenomenon, through neutrophil-derived elastase, could also underlie the abnormal peripheral-blood egress of myeloid progenitors in MMM...
  36. ncbi request reprint Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates
    Ayalew Tefferi
    Division of Hematology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 30:677-80. 2006
    ..In the current study, we show that microcytosis is a frequent laboratory feature in agnogenic myeloid metaplasia and investigate its clinical relevance in the particular setting...
  37. ncbi request reprint Polycythemia vera: scientific advances and current practice
    Ayalew Tefferi
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Semin Hematol 42:206-20. 2005
    ..Despite recent progress in the field, several important issues remain controversial. In this review, we will present the areas of agreement, but also point out where the authors' personal viewpoints differ...
  38. ncbi request reprint Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 108:1158-64. 2006
    ..We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities...
  39. ncbi request reprint Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:166-71. 2005
    ..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP...
  40. ncbi request reprint bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1220-32. 2005
    ..In this article, we outline contemporary diagnostic algorithms for each of these disorders and provide an evidence-based approach to management...
  41. ncbi request reprint Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:1656-60. 2005
    ..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables...
  42. ncbi request reprint Introduction to a cancer symposium for the practitioner
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1085-6. 2005
  43. ncbi request reprint Modern diagnosis and treatment of primary eosinophilia
    A Tefferi
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Acta Haematol 114:52-60. 2005
    ..Allogeneic transplantation offers a viable treatment option for drug-refractory cases...
  44. ncbi request reprint JAK2 in myeloproliferative disorders is not just another kinase
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cell Cycle 4:1053-6. 2005
    ..Taken together, these observations suggest that JAK2(V617F) is an acquired myeloid lineage-specific mutation that engenders a pathogenetic relevance for the PV phenotype in MPD...
  45. ncbi request reprint Atypical myeloproliferative disorders: diagnosis and management
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:553-63. 2006
    ....
  46. doi request reprint Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:14-7. 2010
    ..We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes...
  47. ncbi request reprint A long-term retrospective study of young women with essential thrombocythemia
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 76:22-8. 2001
    ..To describe presenting clinical manifestations, long-term disease complications, prognostic indicators, and outcome of pregnancy for women younger than 50 years with essential thrombocythemia...
  48. ncbi request reprint Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests
    Ayalew Tefferi
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:599-604. 2007
    ....
  49. ncbi request reprint Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Thromb Hemost 33:313-20. 2007
    ..Whether the presence of this specific mutation or its allele burden modifies the risk of thrombosis in patients with MPDs currently is under investigation...
  50. doi request reprint JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Rev 25:229-37. 2011
    ..It is our impression that many more JAK inhibitors need to be evaluated in order to identify the best-in-class in terms of efficacy, toxicity and suitability for future combination treatment programs...
  51. ncbi request reprint Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  52. pmc Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology
    Ayalew Tefferi
    Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Mol Diagn 13:461-6. 2011
    ..The practice of en bloc screening for JAK2V617F, JAK2 exon 12, and MPL mutations is scientifically irrational and economically irresponsible...
  53. ncbi request reprint Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms
    A Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:14-22. 2008
    ..The current review highlights these changes and also provides diagnostic algorithms that are tailored to routine clinical practice...
  54. pmc Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:1188-91. 2011
    ....
  55. ncbi request reprint Iron chelation therapy for myelodysplastic syndrome: if and when
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:197-8. 2006
  56. ncbi request reprint JAK2 mutations and clinical practice in myeloproliferative neoplasms
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 13:366-71. 2007
    ....
  57. doi request reprint Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 22:756-61. 2008
    ..We conclude that low V617F allele burden in PMF might indicate the presence of an overriding V617F-negative clone that confers a more aggressive disease phenotype...
  58. ncbi request reprint Long-term outcome of treatment with ruxolitinib in myelofibrosis
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN
    N Engl J Med 365:1455-7. 2011
    ..The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered...
  59. ncbi request reprint Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood Rev 15:121-31. 2001
    ..Clinicopathologic correlates to these biologic parameters are currently being defined...
  60. doi request reprint 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:386-90. 2008
    ....
  61. ncbi request reprint Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Hematol 80:430-5. 2001
    ..Here we describe a patient who developed pneumomediastinum, pneumopericardium, subcutaneous emphysema and pneumothorax secondary to severe bronchiolitis obliterans complicating the post bone marrow transplantation course...
  62. ncbi request reprint Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1225-7. 2008
  63. ncbi request reprint The pathogenesis of chronic myeloproliferative diseases
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Int J Hematol 73:170-6. 2001
    ..This review discusses some of the current and past observations regarding the pathogenesis of chronic myeloproliferative disorders...
  64. ncbi request reprint Recent progress in the pathogenesis and management of essential thrombocythemia
    A Tefferi
    Mayo Clinic, Division of Hematology and Internal Medicine, 200 First Street SW, Rochester, MN 55095, USA
    Leuk Res 25:369-77. 2001
    ..Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations...
  65. doi request reprint Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
    A Tefferi
    Divisions of Hematology and Hematopathology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:900-4. 2009
    ..98). We conclude that TET2 mutations are frequent in SM, segregate with KITD816V and influence phenotype without necessarily altering prognosis...
  66. ncbi request reprint Suppressors of cytokine signaling and regulation of clonal erythropoiesis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 48:7-8. 2007
  67. doi request reprint Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1356-63. 2011
    ..This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance...
  68. ncbi request reprint A contemporary approach to the diagnosis and management of polycythemia vera
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Rep 2:237-41. 2003
    ..This review outlines a practical approach to diagnosis, in addition to treatment of life-threatening and non-life-threatening complications of PV...
  69. doi request reprint Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 86:292-301. 2011
    ..Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus, and a small risk of disease progression into acute leukemia or myelofibrosis...
  70. doi request reprint TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:905-11. 2009
    ..05). We conclude that TET2 mutations occur in both JAK2V617F-positive and -negative MPN, are more prevalent in older patients, display similar frequencies across MPN subcategories and disease stages, and hold limited prognostic relevance...
  71. ncbi request reprint The forgotten myeloproliferative disorder: myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Oncologist 8:225-31. 2003
    ..New treatment approaches include the use of thalidomide alone or in combination with prednisone and hematopoietic stem cell transplantation...
  72. ncbi request reprint Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2083-8. 2007
    ..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
  73. ncbi request reprint Polycythemia vera: a comprehensive review and clinical recommendations
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:174-94. 2003
    ....
  74. doi request reprint The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos
    Ayalew Tefferi
    Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 115:3842-7. 2009
    ..The revised WHO document continues to promote the recognition of histologic categories as a necessary first step toward the genetic characterization of myeloid malignancies...
  75. doi request reprint Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Ken H Lim
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:790-4. 2009
    ....
  76. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
    ..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...
  77. ncbi request reprint Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia
    Brijesh Arora
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Haematologica 89:1454-8. 2004
    ..This issue is further examined in the current prospective study and clinico-pathological correlates sought...
  78. ncbi request reprint CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 102:3093-6. 2003
    ..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD...
  79. ncbi request reprint JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance
    Alexandra P Wolanskyj
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 131:208-13. 2005
    ..Therefore, although the presence of JAK2(V617F) in ET appears to promote a PV phenotype, it might not carry treatment-relevant information...
  80. ncbi request reprint A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2534-41. 2003
    ..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
  81. ncbi request reprint IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1146-51. 2010
    ..This study shows a relatively high incidence of IDH mutations in blast-phase MPN, regardless of JAK2 mutational status, and the occurrence of similar mutations in chronic-phase PMF...
  82. ncbi request reprint Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Ross L Levine
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 7:387-97. 2005
    ..In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase...
  83. ncbi request reprint In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia
    R A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 17:849-55. 2003
    ....
  84. doi request reprint Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:708-13. 2008
    ..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden...
  85. doi request reprint Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 84:518-24. 2010
    ..The current study was designed to provide additional data in this regard...
  86. ncbi request reprint Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia
    Yinlee Yoong
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 74:124-7. 2005
    ..These results are contrary to previous reports that suggested inferior survival as well as poor response to alpha interferon therapy in CML patients carrying der(9) deletions...
  87. ncbi request reprint Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
    Jaya Kittur
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2279-84. 2007
    ..A possible association with thrombotic complication has also been considered...
  88. doi request reprint The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea
    Shireen Sirhan
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:363-5. 2008
    ..02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV...
  89. ncbi request reprint Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay
    Cody A Koch
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 127:34-9. 2004
    ..86% test accuracy). The current study suggests that PRP serotonin concentration might be considered as one of the several biological markers that complement each other for the diagnosis of PV...
  90. ncbi request reprint Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia
    Michelle A Elliot
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Eur J Haematol 68:175-9. 2002
    ....
  91. ncbi request reprint Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Intern Med 43:540-7. 2004
    ..Among the novel agents tested, thalidomide seems the most promising although newer agents are on the horizon...
  92. ncbi request reprint Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Stem Cells 25:2358-62. 2007
    ..These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell...
  93. ncbi request reprint Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
    Naseema Gangat
    Division of Hematology, Department of Medicine, Laboratory Medicine, and Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 138:354-8. 2007
    ..The current study highlighted the prognostic relevance of leucocytosis on various aspects of the disease in PV...
  94. ncbi request reprint Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time
    Terra L Lasho
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 135:683-7. 2006
    ..We conclude that MPLW515L/K and JAK2V617F are both early events in MMM and allele burden, rather than the mere presence of these mutations, might be relevant to phenotypic variation in myeloproliferative disorders...
  95. ncbi request reprint Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia
    Terra L Reeder
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1981-3. 2003
    ..The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed interpatient heterogeneity in clonal constitution...
  96. ncbi request reprint Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 106:623-30. 2006
    ..The current study describes the natural history of AMM in transplant-eligible patients and proposes a new prognostic scoring system that favorably compares with other established models...
  97. doi request reprint Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Am J Hematol 85:238-42. 2010
    ..We conclude that neither the SCLL phenotype nor blood eosinophilia is a consistent feature of FGFR1-associated 8p11.2 translocations; conversely, FISH might not always reveal FGFR1 involvement in typical SCLL...
  98. doi request reprint Molecular diagnosis of myeloproliferative neoplasms
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Expert Rev Mol Diagn 9:481-92. 2009
    ..In patients with clonal eosinophilic disorders and mast cell disease, the use of molecular diagnostics to identify novel mutations and gene rearrangements, has resulted in superior diagnostic and therapeutic strategies...
  99. ncbi request reprint Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 30:161-5. 2002
    ..03). Relapse-free survival was similar for the two groups. We conclude that omitting day +11 MTX appears to increase the risk of severe acute GVHD...